Brought to you by 
Allergan buys migraine drug partner MAP for $884mm
04 Jun 2021
Executive Summary
Allergan Inc. is buying publicly traded MAP Pharmaceuticals Inc. (using formulation and inhalation technologies to develop neurological drug candidates) for $884mm in cash, or $25 per share (a 57% premium). The acquisition is Allergan’s second-largest to date, coming in behind the company’s 2005 takeover of aesthetics firm Inamed for $3.1bn.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
- Site Specific
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Allergan buys migraine drug partner MAP for $884mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice